Esperion Q3 2024 Earnings Report
Key Takeaways
Esperion reported a strong third quarter in 2024, marked by significant revenue growth and prescription increases. Total revenue increased by 52% year-over-year to $51.6 million, driven by a 53% increase in U.S. net product revenue. Key achievements included expanded product labels, a scaled-up commercial team, and successful new indication launches, contributing to double-digit prescription growth. The company also strengthened its balance sheet by monetizing European royalties and paying off a revenue interest facility.
Total revenue increased by 52% year-over-year to $51.6 million.
U.S. net product revenue grew by 53% year-over-year to $31.1 million.
Total retail prescription equivalents increased by 12% compared to the second quarter.
New to brand prescriptions grew by 18% from the second quarter.
Esperion
Esperion
Esperion Revenue by Segment
Forward Guidance
The company reiterates its full year 2024 operating expense guidance, which is expected to be approximately $225 million to $245 million, including $20 million in non-cash expenses related to stock compensation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income